Lung Cancer Clinical Trial
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Summary
This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been shown to provide excellent results when used in early stage lung cancer, but has not yet been applied to patients with more advanced disease.
Full Description
PRIMARY OBJECTIVE:
To test the safety and tolerability of an alternative fractionation regimen in locally advanced non-small cell lung cancer (NSCLC), consisting of 44 Gy with concurrent chemotherapy followed by a stereotactic body radiation therapy (SBRT) boost to remaining parenchymal and nodal disease. The maximum tolerated dose of the SBRT boost will be determined.
SECONDARY OBJECTIVES:
To assess local control.
To assess distant metastasis and patterns of failure.
To assess overall survival at 1 and 2 years.
OUTLINE: This is a dose-escalation study of radiation therapy and SBRT.
Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.
After completion of study treatment, patients are followed up for 5 years.
Eligibility Criteria
Inclusion Criteria:
Biopsy proven NSCLC, within 8 weeks prior to patient registration
Unresectable disease
Clinical stage Tx, T1-T4, N1-3, M0
Karnofsky performance status (KPS) ≥ 70
Pretreatment positron emission tomography (PET) CT scan to rule out metastatic disease
The primary tumor may not be larger than 8 cm in maximum dimension
If the primary tumor is central in location, defined as within 2 cm from the tracheobronchial tree, it must be no larger than 5 cm
Mediastinal and hilar lymphadenopathy can be no larger than 5 cm at any nodal station
Pretreatment brain CT with contrast or brain MRI to rule out metastases
Pathologic assessment of the mediastinum to document involved nodal stations
All of the above inclusion criteria must occur within 8 weeks prior to patient registration, with the exception of pathologic assessment of the mediastinum and biopsy to confirm NSCLC, which can be done within 12 weeks of patient registration
Exclusion Criteria:
Prior history of lung cancer
Pregnancy
Prior history of radiation to the chest
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Atlanta Georgia, 30303, United States
Atlanta Georgia, 30308, United States
Atlanta Georgia, 30322, United States
Saint Louis Missouri, 63110, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.